Letolizumab

Letolizumab is a monoclonal antibody designed for the treatment of autoimmune diseases. It is currently under development by Biocon Biologics and Viatris.

History[edit | edit source]

Letolizumab was originally developed by Biocon Biologics, a subsidiary of Biocon, an Indian biopharmaceutical company. In 2020, Biocon Biologics partnered with Viatris, a global healthcare company, to further develop and commercialize the drug.

Mechanism of Action[edit | edit source]

Letolizumab is a monoclonal antibody that targets the CD6 protein, a surface molecule present on T cells. By binding to CD6, letolizumab inhibits the activation and proliferation of T cells, thereby reducing the immune response that contributes to autoimmune diseases.

Clinical Trials[edit | edit source]

Letolizumab has undergone several clinical trials to evaluate its safety and efficacy in treating autoimmune diseases. These trials have shown promising results, with letolizumab demonstrating a good safety profile and potential efficacy in reducing symptoms of autoimmune diseases.

Potential Uses[edit | edit source]

Letolizumab is being investigated for use in a variety of autoimmune diseases, including rheumatoid arthritis, psoriasis, and multiple sclerosis. Further clinical trials are needed to confirm its efficacy and safety in these conditions.

See Also[edit | edit source]

Letolizumab Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.